Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quadrivalent HPV vaccination after effective treatment of Anal Intraepithelial Neoplasia in HIV+ men

Trial Profile

Quadrivalent HPV vaccination after effective treatment of Anal Intraepithelial Neoplasia in HIV+ men

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Anal intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use
  • Acronyms VACCAIN-P
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Mar 2018 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
    • 13 Mar 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top